Isabl Inc.
Andrew Kung serves as the Chairman of the Department of Pediatrics at Memorial Sloan Kettering Cancer Center since July 2016. Additionally, Andrew is a Co-Founder and Board member of Isabl and holds positions on the Scientific Advisory Boards of multiple companies including Karyopharm Therapeutics Inc., Emendo Biotherapeutics, and DarwinHealth. Prior experience includes leadership roles at Columbia University Irving Medical Center and Dana-Farber Cancer Institute, where Andrew contributed to pediatric hematology/oncology and held various academic positions. Education includes a Doctor of Philosophy in Cancer Biology and a Doctor of Medicine from Stanford University School of Medicine, as well as a Bachelor of Science in Biochemistry from Florida State University.
This person is not in any teams
This person is not in any offices
Isabl Inc.
Isabl specializes in the fields of whole-genome cancer diagnostics. The company is currently looking to partner with oncology centers nationwide to showcase the value of using whole-genome sequencing in clinical cancer care.